Press Releases

Date Title and Summary Additional Formats  
Toggle Summary Karyopharm Reports Second Quarter 2020 Financial Results and Highlights Recent Company Progress
-- Second Quarter 2020 XPOVIO Net Product Sales of $18.6 Million; Strongest Quarterly Sales Since July 2019 Launch --   -- XPOVIO Approved by FDA as a New Treatment for Patients with Relapsed or Refractory DLBCL; Commercial Rollout Began Immediately Upon Approval --   -- Supplemental New Drug
View HTML
Toggle Summary Karyopharm Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
NEWTON, Mass. , Aug. 3, 2020 /PRNewswire/ -- Karyopharm Therapeutics Inc. (Nasdaq: KPTI), an innovation-driven pharmaceutical company, today announced that the Compensation Committee of Karyopharm's Board of Directors granted stock options to purchase an aggregate of 27,300 shares of Karyopharm's
View HTML
Toggle Summary Karyopharm to Report Second Quarter 2020 Financial Results on August 4, 2020
− Conference Call Scheduled for Tuesday, August 4, 2020, at 8:30 a.m. ET − NEWTON, Mass. , July 28, 2020 /PRNewswire/ --  Karyopharm Therapeutics Inc. (Nasdaq:KPTI) an innovation-driven pharmaceutical company, today announced that it will report second quarter 2020 financial results on Tuesday,
View HTML
Toggle Summary U.S. Food and Drug Administration Accepts Karyopharm’s Supplemental New Drug Application for XPOVIO® (selinexor) as a Treatment for Patients with Multiple Myeloma After At Least One Prior Line of Therapy
NEWTON, Mass. , July 20, 2020 (GLOBE NEWSWIRE) -- Karyopharm Therapeutics Inc. (Nasdaq:KPTI), an innovation-driven pharmaceutical company, today announced that the U.S. Food and Drug Administration (FDA) has accepted for filing its supplemental New Drug Application (sNDA) seeking approval for
View HTML
Toggle Summary Karyopharm Enters Into a Collaboration with National Cancer Institute to Advance XPOVIO® (selinexor) Research
NEWTON, Mass. , July 17, 2020 (GLOBE NEWSWIRE) -- Karyopharm Therapeutics Inc. (Nasdaq:KPTI), an innovation-driven pharmaceutical company, today announced that it has entered into a Cooperative Research and Development Agreement (CRADA) with the National Cancer Institute’s (NCI) Cancer Therapy
View HTML
Toggle Summary Karyopharm Announces Preliminary Unaudited Second Quarter Product Sales for XPOVIO® (selinexor)
-- Preliminary Unaudited XPOVIO Net Product Sales of Approximately $18.5 Million for the  Second Quarter 2020 -- -- Strongest Quarterly XPOVIO Sales Since July 2019 Commercial Launch -- NEWTON, Mass. , July 14, 2020 (GLOBE NEWSWIRE) -- Karyopharm Therapeutics Inc.
View HTML
Toggle Summary Karyopharm Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
NEWTON, Mass. , July 01, 2020 (GLOBE NEWSWIRE) -- Karyopharm Therapeutics Inc. (Nasdaq: KPTI), an innovation-driven pharmaceutical company, today announced that the Compensation Committee of Karyopharm’s Board of Directors granted stock options to purchase an aggregate of 41,700 shares of
View HTML
Toggle Summary Karyopharm Announces Publication of XPOVIO® (Selinexor) Phase 2b SADAL Study Results in The Lancet Haematology
NEWTON, Mass. , June 24, 2020 (GLOBE NEWSWIRE) -- Karyopharm Therapeutics Inc. (Nasdaq:KPTI), an innovation-driven pharmaceutical company, today announced that the results of the Phase 2b SADAL ( S elinexor A gainst D iffuse A ggressive L ymphoma) study evaluating XPOVIO in patients with relapsed
View HTML
Toggle Summary Karyopharm Announces FDA Approval of XPOVIO® (selinexor) for the Treatment of Patients with Relapsed or Refractory Diffuse Large B-cell Lymphoma (DLBCL)
-- XPOVIO is Now the Only Single-Agent, Oral Therapy Approved for the Treatment of Patients with Relapsed or Refractory Diffuse Large B-cell Lymphoma, Including DLBCL Arising from Follicular Lymphoma -- -- XPOVIO is the First and Only FDA-Approved Drug for Use in Both Multiple Myeloma and DLBCL --
View HTML
Toggle Summary Karyopharm Presents XPOVIO® (selinexor) and Eltanexor Data at the European Hematology Association 2020 Virtual Annual Meeting
-- Selinexor Demonstrates a Significant Survival Benefit in Patients with Relapsed or Refractory DLBCL and Durable Responses in Important DLBCL Patient Subgroups, Including Those with Primary Refractory Disease and Regardless of Number of Prior Therapies -- NEWTON, Mass.
View HTML